Randomized trial of an intensified, multifactorial intervention in patients with advanced‐stage diabetic kidney disease: Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT‐Japan)

Published on Feb 1, 2021in Journal of Diabetes Investigation3.761
· DOI :10.1111/JDI.13339
Kenichi Shikata51
Estimated H-index: 51
(Okayama University),
Masakazu Haneda31
Estimated H-index: 31
(Asahikawa Medical University)
+ 12 AuthorsDiabetic Nephropathy Remission
AIMS/INTRODUCTION We evaluated the efficacy of multifactorial intensive treatment (IT) on renal outcomes in patients with type 2 diabetes and advanced stage of diabetic kidney disease (DKD). MATERIALS AND METHODS Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan) is a multi-centered, open-labeled, randomized controlled trial with a 5-year follow-up. We randomly assigned 164 patients with advanced stage of DKD (urinary albumin-to-creatinine ratio ≥300 mg/g creatinine, serum creatinine level: 1.2-2.5 mg/dl in male and 1.0-2.5 mg/dl in female) to receive either IT or conventional treatment (CT). The primary composite outcome was end stage kidney failure, doubling of serum creatinine, or death from any cause, which was assessed in the intention-to treat population. RESULTS The IT tended to reduce the risk of primary endpoints as compared to CT, but the difference between treatment groups did not reach the statistically significant level (hazard ratio (HR), 0.69; 95% confidence interval [CI], 0.43 to 1.11; P=0.13). Meanwhile, the decrease in serum LDL cholesterol level and the use of statin were significantly associated with the decrease in primary outcome (HR, 1.14; 95% CI, 1.05 to 1.23; p<0.001 and HR, 0.53; 95% CI, 0.28 to 0.998; p<0.05, respectively). The incidence of adverse events was not different between treatment groups. CONCLUSIONS The risk of kidney events tended to decrease by IT although it was not statistically significant. Lipid control using statin was associated with lower risk of kidney event. Further follow-up study may show the effect of IT in patients with advanced DKD.
📖 Papers frequently viewed together
2 Citations
73 Citations
13 Citations
#1Vlado Perkovic (UNSW: University of New South Wales)H-Index: 93
#2Meg Jardine (UNSW: University of New South Wales)H-Index: 43
Last. Kenneth W. MahaffeyH-Index: 113
view all 24 authors...
Abstract Background Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium...
1,498 CitationsSource
#1Kohjiro Ueki (UTokyo: University of Tokyo)H-Index: 64
#2Takayoshi Sasako (UTokyo: University of Tokyo)H-Index: 12
Last. Masamitsu NakazatoH-Index: 1
view all 155 authors...
Summary Background Limited evidence suggests that multifactorial interventions for control of glucose, blood pressure, and lipids reduce macrovascular complications and mortality in patients with type 2 diabetes. However, safe and effective treatment targets for these risk factors have not been determined for such interventions. Methods In this multicentre, open-label, randomised, parallel-group trial, undertaken at 81 clinical sites in Japan, we randomly assigned (1:1) patients with type 2 diab...
118 CitationsSource
Background Diabetes is the leading cause of end-stage kidney disease (ESKD) around the world. Blood pressure lowering and glucose control are used to reduce diabetes-associated disability including kidney failure. However there is a lack of an overall evidence summary of the optimal target range for blood glucose control to prevent kidney failure. Objectives To evaluate the benefits and harms of intensive (HbA1c < 7% or fasting glucose levels < 120 mg/dL versus standard glycaemic control (HbA1c ...
37 CitationsSource
#1Jens Oellgaard (University of Southern Denmark)H-Index: 8
#2Peter Gæde (University of Southern Denmark)H-Index: 20
Last. Oluf Pedersen (Novo Nordisk Foundation)H-Index: 141
view all 6 authors...
In the present post hoc analyses we studied the impact of intensified, multifactorial treatment on renal outcomes in patients with type 2 diabetes and microalbuminuria enrolled in the Steno-2 Study. Outcome measures were progression to macroalbuminuria, decline in the glomerular filtration rate (GFR), and development of end stage renal disease (ESRD). In total, 160 patients with type 2 diabetes and microalbuminuria were recruited and assigned to conventional or intensified therapy targeting mult...
47 CitationsSource
#1Steven P. Marso (UTSW: University of Texas Southwestern Medical Center)H-Index: 61
#2Gilbert H. Daniels (Harvard University)H-Index: 57
Last. John B. Buse (UNC: University of North Carolina at Chapel Hill)H-Index: 118
view all 15 authors...
BackgroundThe cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. MethodsIn this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo. The primary composite outcome in the time-to-event analysis was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The prima...
3,200 CitationsSource
#1Xiaole Su (Shanxi Medical University)H-Index: 2
#2Lu Zhang (PKU: Peking University)H-Index: 2
Last. Hong Zhang (PKU: Peking University)H-Index: 36
view all 7 authors...
Background The effects of statin administration on kidney disease outcomes remain controversial. We undertook a systematic review and meta-analysis to assess the efficacy of statins on kidney outcomes. Study Design We conducted a meta-analysis of randomized controlled trials (RCTs) using MEDLINE (1946 to August 31, 2015), EMBASE (1966 to August 31, 2015), and the Cochrane Library database (no date restriction). Setting & Population Adults who were not receiving dialysis, for whom kidney disease ...
71 CitationsSource
#1Muh Geot Wong (The George Institute for Global Health)H-Index: 17
#2Vlado Perkovic (The George Institute for Global Health)H-Index: 93
Last. Sophia Zoungas (Monash University)H-Index: 64
view all 18 authors...
OBJECTIVE The Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial reported that intensive glucose control prevents end-stage kidney disease (ESKD) in patients with type 2 diabetes, but uncertainty about the balance between risks and benefits exists. Here, we examine the long-term effects of intensive glucose control on risk of ESKD and other outcomes. RESEARCH DESIGN AND METHODS Survivors, previously randomized to intensive or standard glucose...
106 CitationsSource
#1Dick de Zeeuw (UMCG: University Medical Center Groningen)H-Index: 115
#2Deborah Anzalone (AstraZeneca)H-Index: 8
Last. Donald G. Vidt (Cleveland Clinic)H-Index: 40
view all 11 authors...
Summary Background The role of lipid-lowering treatments in renoprotection for patients with diabetes is debated. We studied the renal effects of two statins in patients with diabetes who had proteinuria. Methods PLANET I was a randomised, double-blind, parallel-group trial done in 147 research centres in Argentina, Brazil, Bulgaria, Canada, Denmark, France, Hungary, Italy, Mexico, Romania, and the USA. We enrolled patients with type 1 or type 2 diabetes aged 18 years or older with proteinuria (...
78 CitationsSource
#1Hans-Henrik Parving (UCPH: University of Copenhagen)H-Index: 103
#1Hans-Henrik Parving (UCPH: University of Copenhagen)H-Index: 58
Last. Peter Rossing (Steno Diabetes Center)H-Index: 100
view all 2 authors...
In 2014, key studies in the field of diabetic nephropathy highlighted the importance of albuminuria as a predictor of cardiovascular risk and showed that the incidence of renal and cardiovascular complications is decreasing. Promising efficacy data were obtained with atrasentan, whereas a trial of bardoxolone methyl led to safety concerns.
10 CitationsSource
#1Mark E. Molitch (NU: Northwestern University)H-Index: 92
#2Amanda I AdlerH-Index: 32
Last. Carl Erik Mogensen (Aarhus University Hospital)H-Index: 22
view all 10 authors...
The incidence and prevalence of diabetes mellitus (DM) continue to grow markedly throughout the world, due primarily to the increase in type 2 DM (T2DM). Although improvements in DM and hypertension management have reduced the proportion of diabetic individuals who develop chronic kidney disease (CKD) and progress to end-stage renal disease (ESRD), the sheer increase in people developing DM will have a major impact on dialysis and transplant needs. This KDIGO conference addressed a number of con...
143 CitationsSource
Cited By3
#1Dong Peng (CQMU: Chongqing Medical University)H-Index: 1
view all 5 authors...
#1Daiji Kawanami (Fukuoka University)H-Index: 17
#1Daiji Kawanami (Fukuoka University)H-Index: 4
Last. Makito Tanabe (Fukuoka University)H-Index: 14
view all 5 authors...
Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease (ESRD) worldwide. Dipeptidyl peptidase (DPP)-4 inhibitors are widely used in the treatment of patients with type 2 diabetes (T2D). DPP-4 inhibitors reduce glucose levels by inhibiting degradation of incretins. DPP-4 is a ubiquitous protein with exopeptidase activity that exists in cell membrane-bound and soluble forms. It has been shown that an increased renal DPP-4 activity is associated with the development of DKD. A...
3 CitationsSource